Rethinking nuclease strategy to improve yield, product quality, and manufacturing economics in viral vector production
12 Jan 2026Viral vector manufacturing is at an inflection point. As demand accelerates, manufacturing cost and scalability are increasingly limiting patient access to life-saving therapies. Despite extensive optimization of upstream productivity and downstream unit operations, nuclease strategy remains an under-exploited lever with impact on yield, cost per dose, and product quality profile.
This white paper analyzes how optimized nuclease selection transforms viral vector manufacturing economics. Using experimentally validated data and cost modeling across AAV and lentiviral workflows, it shows how SAN HQ and M-SAN HQ enable superior chromatin clearance under process-relevant salt conditions, doubling recovery, improving downstream robustness, reducing nuclease costs by over 70%, and lowering cost of goods per dose by approximately 40%.
Related Products
Request Quote for All Products
Bioprocessing Salt Active Nucleases - Physiological Conditions
ArcticZymesNonspecific endonuclease is highly active at physiological conditions (125–200 mM) for DNA removal during protein production, vaccine manufacturing, and viral vector preparation. M-SAN High Quality can be used directly in cell media, which improves efficiency and yield. Designed to replace Benzonase without workflow changes. M-SAN HQ excels in ensuring higher purity and efficiency. High purity (≥ 99%). Compatible with ELISA kit.
Bioprocessing Salt Active Nucleases - High Salt Conditions
ArcticZymesSalt Active Nuclease High Quality (SAN HQ) is a Bioprocessing Grade nuclease available in GMP grade developed as the most efficient solution for removal of both single and double stranded DNA and RNA at high salt conditions(400–700 mM). It excels in DNA removal for robust viral vectors like Adenovirus and AAV, ensuring superior product purity while improving DSP. Ideal for gene therapy and vaccine manufacturing. Triton free available.